Brand-Name Drug

Key facts

Drug pathway

New Drug Application under FD&C Act Section 505(b)

Biologic pathway

Biologics License Application under PHS Act Section 351(a)

Listed in

FDA Orange Book (drugs) and Purple Book (biologics)

Regulatory status of the term

Informal label; regulators classify products by application type

What is a brand-name drug?

A brand-name drug carries a proprietary name, such as Lipitor or Humira, chosen by its sponsor and reviewed by the Food and Drug Administration (FDA) to avoid confusion with other products. The same product also has a nonproprietary name, such as atorvastatin or adalimumab, that describes the active ingredient.

Most brand-name drugs are innovator products: the first version of a molecule to reach the market, backed by the sponsor's own clinical trials. Patents and FDA regulatory exclusivities protect them and together determine when generic or biosimilar competitors can launch.

The phrase is a commercial label, not a regulatory category. Some generics are sold under trade names (branded generics), and some brand companies sell their own product without the trade name as an authorized generic.

How brand-name drugs reach and hold the market

Market protection comes from separate systems that run on different clocks:

• Approval: small-molecule drugs are approved through a New Drug Application (NDA) under Section 505(b) of the Federal Food, Drug, and Cosmetic Act; biologics are licensed through a Biologics License Application (BLA) under Section 351(a) of the Public Health Service Act.
• Patents: issued by the U.S. Patent and Trademark Office. NDA holders list certain drug substance, drug product and method-of-use patents in the Orange Book.
• Regulatory exclusivity: granted by the FDA independently of patents, for example 5 years for a new chemical entity, 7 years for an orphan drug indication and 12 years for a biologic reference product.
• Loss of exclusivity: once patents and exclusivities expire or are successfully challenged, generics can enter through an Abbreviated New Drug Application (ANDA) and biosimilars through Section 351(k).

Why brand-name drug status matters

Brand or generic status changes how a product is priced, paid for and sold:

• Price forecasting: brand prices and volumes typically fall sharply once multiple generics launch, so loss-of-exclusivity dates drive revenue forecasts and patent cliff analysis.
• Medicaid: the Medicaid Drug Rebate Program classifies NDA and BLA products as single source or innovator multiple source drugs, which carry a higher statutory basic rebate percentage than generics.
• Medicare Part D: the Manufacturer Discount Program, which began in 2025, applies to brand-name drugs and biologics rather than generics.
• Pricing benchmarks: the NADAC file flags each drug as brand or generic for rate setting, and pharmacy reimbursement formulas often differ by class.
• Commercial targeting: brand manufacturers fund sales forces and patient support programs, so prescriber-level data on brand use informs territory planning.